Successful Treatment with Fludarabine in Two Cases of Angioimmunoblastic Lymphadenopathy with Dysproteinemia

• Published in: Leukemia & lymphoma Vol. 34; no. 5-6; pp. 597 - 601
• Main Authors: Hast, Robert, Jacobsson, BjÖRn, Petrescu, Anna, Hjalmar, Viktoria
• Format: Journal Article
• Language: English
• Published: United States Informa UK Ltd 1999; Taylor & Francis
• Subjects: Aged; Aged, 80 and over; AILD; angioimmunoblastic lymphadenopathy with dysproteinemia; Antineoplastic Agents - therapeutic use; Female; Fludarabine; Humans; Immunoblastic Lymphadenopathy - drug therapy; Immunoblastic Lymphadenopathy - pathology; Lymphoma, T-Cell - drug therapy; Lymphoma, T-Cell - pathology; malignant lymphoma; Medicin och hälsovetenskap; Middle Aged; Remission Induction; T-cells; Vidarabine - analogs & derivatives; Vidarabine - therapeutic use
• ISSN: 1042-8194; 1029-2403
• DOI: 10.3109/10428199909058489

Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) is today recognized as a T-cell lymphoma which in most cases runs an aggressive course. The diagnosis is often difficult because of the varying clinico-pathological picture. Less than a third of the patients can be expected to have long-term remissions even after multiagent chemotherapy. Complete remissions have been reported after the use of interferon-alpha, cyclosporin A. and recently purine analogues in a few patients. We now report two cases of AILD that had unmaintained remissions for 32 and 10 months, respectively, after fludarabine therapy. In one of the patients fludarabine was used up-front and in the other after she had proved to be resistant to CHOP treatment. No severe infectious complications were noted. The use of purine analogues should be investigated further in AILD.